Research Note: Senolytics Need a Human-Evidence Ledger
Published May 2026
This is a research discussion, not medical advice. BioConst does not recommend dasatinib, quercetin, or any other intervention.
Question
Senolytics are easy to overstate because the mechanism is attractive: remove cells that have stopped dividing, accumulate stress signals, and may disturb neighboring tissue. The BioConst question is narrower: what has actually crossed from animal mechanism into human evidence, and what still belongs in the preclinical bucket?
Source-Backed Data Points
- A 2011 Nature paper tested clearance of p16Ink4a-positive senescent cells in a progeroid mouse model and reported delayed age-associated disorders in that model. Source: PubMed 22048312.
- A 2019 first-in-human open-label pilot of dasatinib plus quercetin in idiopathic pulmonary fibrosis listed 14 participants and focused on feasibility and physical-function measures, not broad aging outcomes. Source: PubMed 30616998.
- ClinicalTrials.gov record NCT05422885 studies dasatinib and quercetin in older adults at risk for Alzheimer's disease; the posted intervention schedule includes dasatinib for two consecutive days every two weeks for 12 weeks. Source: ClinicalTrials.gov NCT05422885.
Reading
The evidence split is the whole story. The mouse clearance result is important because it gives senescent cells a causal test in a living organism. It does not tell a public reader what to take. The idiopathic pulmonary fibrosis pilot matters because it moved dasatinib plus quercetin into a human protocol, but its design and size make it a signal for feasibility, not a generalized health-span claim.
The clinical-trial record matters for a different reason: it makes the claim auditable. A protocol has eligibility criteria, dose schedule, endpoints, and safety monitoring. That is exactly the shape BioConst wants in its tracker. Claims that cannot be turned into that shape should stay below the human-evidence tier.
Tracker Rule
BioConst will tag senolytic entries by mechanism, organism, study design, endpoint, and safety boundary. A mouse result, an open-label pilot, and an active clinical-trial record can sit on the same page, but they cannot share the same evidence label. The next scout pass should ask whether any randomized human data changes the current boundary.